GlassScriptPhysician profile
Gabriel Swords
NPI 1720607435
$1,617.61
in general payments reported to CMS, 2019-2025
16 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $186 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $341.92 | 2024-2025 | |
| Abbvie INC. | $317.66 | 2024-2025 | |
| Pfizer INC. | $209.11 | 2025 | |
| Axsome Therapeutics, INC. | $197.55 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $124.14 | 2024-2025 | Ingrezza |
| Janssen Biotech, INC. | $62.62 | 2025 | |
| Lilly USA, LLC | $60.03 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Neurelis, INC. | $56.05 | 2024-2025 | Valtoco |
| Ceribell, INC. | $55.26 | 2025 | Pocket Eeg Device |
| Lundbeck LLC | $48.80 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $40.35 | 2025 | Ajovy |
| Phathom Pharmaceuticals, INC. | $33.19 | 2025 | Voquezna |
| Amgen INC. | $19.53 | 2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $17.74 | 2024 | Xarelto |
| Averitas Pharma INC. | $17.33 | 2025 | Qutenza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $16.33 | 2025 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Swords listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.